Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The company’s lead FDA approved commercial product, NUZYRA® (omadacycline) is a once-daily intravenous and oral antibiotic for the treatment of adult patients with CABP and ABSSSI caused by susceptible pathogens.
Paratek has entered into a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.
Under a broad-based Project BioShield contract with Biomedical Advanced Research and Development Authority, or BARDA, which is a part of the United States Department of Health and Human Services and the Office of the Assistant Secretary for Preparedness and Response, NUZYRA® is being studied against anthrax, a pathogenic agent that potentially causes an infectious disease of public health and biodefense importance.
Paratek’s second FDA approved commercial product, SEYSARA®(sarecycline), is marketed by Almirall, LLC in the U.S. as a new once-daily oral therapy for the treatment of moderate to severe acne vulgaris. Paratek also granted a license to Almirall for SEYSARA in the greater China region, which includes the Peoples Republic of China, Hong Kong, and Macau. Almirall plans to develop sarecycline for acne in China, with a submission to the China National Medical Products Administration expected in 2023. Paratek retains development and commercialization rights to sarecycline in the rest of the world.
Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.
February Corporate PresentationView